Document Detail

Differential effect of insulin like growth factor-I on constriction of human uterine and placental arteries.
MedLine Citation:
PMID:  22948758     Owner:  NLM     Status:  MEDLINE    
CONTEXT: Discrete regulation of the uterine and placental vasculatures is an important feature of uteroplacental perfusion and pregnancy success because appropriate maternal/fetal exchange of nutrients and gases is crucial for normal fetal growth. Placental vasculature lacks autonomic innervation so tone is controlled by locally derived vasoactive factors. IGF-I, which is produced by the placenta, is critical for normal fetal growth and studies of animal vascular systems have shown that IGF-I regulates vasomotor tone.
OBJECTIVE: The objective of the study was to determine whether IGF-I directly alters human placental and myometrial arterial tone in vitro.
PARTICIPANTS: Women with uncomplicated pregnancy delivering a singleton infant at term participated in the study.
SETTING: The study was conducted at university hospital laboratories.
MAIN OUTCOME MEASURE(S): Comparison of arterial tension measured before and after exposure to IGF-I.
DESIGN: Placental and myometrial arteries were mounted on a wire myograph, exposed to the constrictor U46619 (10(-10) to 10(-5) m), returned to baseline tension, and then incubated with IGF-I (0-500 ng/ml) for various time points before performing a second dose-response curve to U46619. IGF-I receptor protein expression was assessed.
RESULTS: IGF-I did not acutely alter the response of placental arteries to U46619. Exposure of myometrial arteries to IGF-I caused a rightward shift of U46619 dose-response curves (P < 0.05); EC(50) data were significantly increased at 30 (15.5 ± 2.8 vs. 133 ± 44 nm, before and after IGF treatment, respectively) and 60 min (10.9 ± 1.9 vs. 146 ± 47 nm). Placental and myometrial arteries had a similar IGF-I receptor expression profile.
CONCLUSIONS: IGF-I acutely modulates the vasomotor tone of human myometrial, but not placental, arteries, suggesting that IGF-I regulates the delivery of maternal blood to the placenta.
Jemma J Corcoran; Jayne C Charnock; Julie Martin; Michael J Taggart; Melissa Westwood
Related Documents :
23314718 - Fetal abnormal growth associated with substance abuse.
23525628 - The impact of different sides of the absent umbilical artery on fetal growth in an isol...
15937188 - Pseudomonas syringae type iii chaperones shco1, shcs1, and shcs2 facilitate translocati...
12070538 - Thyroid disease and pregnancy.
17601508 - Sonographic evaluation of ectopic pregnancy.
7632638 - Fertility and pregnancy outcome following large loop excision of the cervical transform...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2012-09-04
Journal Detail:
Title:  The Journal of clinical endocrinology and metabolism     Volume:  97     ISSN:  1945-7197     ISO Abbreviation:  J. Clin. Endocrinol. Metab.     Publication Date:  2012 Nov 
Date Detail:
Created Date:  2012-11-06     Completed Date:  2013-01-25     Revised Date:  2014-07-31    
Medline Journal Info:
Nlm Unique ID:  0375362     Medline TA:  J Clin Endocrinol Metab     Country:  United States    
Other Details:
Languages:  eng     Pagination:  E2098-104     Citation Subset:  AIM; IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid / pharmacology
Insulin-Like Growth Factor I / pharmacology*
Placenta / blood supply*,  drug effects,  metabolism
Receptor, IGF Type 1 / metabolism
Uterine Artery / drug effects*,  metabolism,  physiology
Vasoconstriction / drug effects*,  physiology
Vasoconstrictor Agents / pharmacology
Reg. No./Substance:
0/Vasoconstrictor Agents; 67763-96-6/Insulin-Like Growth Factor I; 76898-47-0/15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; EC, IGF Type 1

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Expression of the Ring Ligase PRAJA2 in Thyroid Cancer.
Next Document:  Maternal Pregravid Weight Is the Primary Determinant of Serum Leptin and Its Metabolic Associations ...